Research Alliance Corp III(RACC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 29.66% | Shs Outstand | 7.8M | Perf Week | -8.65% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.4M | Perf Month | -61.43% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 69.59% | Short Float | 0.08% | Perf Quarter | 8.86% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.07 | Perf Half Y | - |
| Sales | - | P/B | 1.39 | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | 10.68% |
| Book/sh | 8.13 | P/C | 123.87 | EPS past 3/5Y | - | ROE | - | 52W High | -66.27% ($33.50) | Perf Year | - |
| Cash/sh | 0.09 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 10.68% ($10.21) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 14.87% 12.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.98 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.3 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 24.27 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.3 | Sales Q/Q | - | SMA20 | -41.54% ($19.33) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -35.77% ($17.59) | Rel Volume | 0.27 | Prev Close | $11.44 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -25.34% ($15.14) | Avg Volume(3M) | 0.08M | Price | $11.3 |
| IPO | 2026/5/20 | Option/Short | No/Yes | Trades | 494 | Volume | 21,401 | Change | -1.22% |
Company
RACC is a Financial sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Research Alliance III (RACC) is a US special purpose acquisition company (SPAC) formed to identify and combine with promising businesses in the biotechnology field by fully leveraging the sponsor group's expertise in bio venture capital and its healthcare network.
Over the past 1 year, on the lower side
66% below its 1-year high.
RACC makes money exceptionally well
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 69.6%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $103M.
RACC $103M PER -
LION $3B PER -
BBCQ $2B PER -
CCXI $686M PER -
FAQ
What kind of company is RACC?
RACC belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of RACC?
The market cap of RACC is approximately $103M, ranking 4,545 within its sector.
What is the 52-week high and low for RACC?
RACC has recorded a 52-week high of $33.50 and a low of $10.21.
